Premium
Antiparkinsonian activity of (+)‐PHNO in the MPTP‐treated common marmoset
Author(s) -
Nomoto M.,
Stahl S.,
Jenner P.,
Marsden C. D.
Publication year - 1987
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.870020105
Subject(s) - mptp , marmoset , medicine , dopamine , dopamine agonist , oral administration , pharmacology , parkinson's disease , agonist , anesthesia , disease , dopaminergic , biology , paleontology , receptor
Administration of MPTP (1–4 mg/kg ip daily for 5–7 days) to common marmosets induced persistent parkinsonian motor deficts. The subcutaneous adminstration of (+)‐PHNO [(+)‐4‐propyl‐9‐hydroxynaphtoxazine; 1–4 μ/kg] caused a dose‐dependent reversal of the akinesia and incoordination of movement. Similarly, oral administration of (+)‐PHNO (5–20 μ/kg) caused an equivalent reversal of the motor abnormalities. No dyskinetic phenomena were induced by (+)‐PHNO on oral or subcutaneous administration. Oral or subcutaneous administration of (+)‐PHNO to normal control marmosets also increased the usual repetoire of motor behaviour, but this was not as marked as in MPTP‐treated animals. (+)‐PHNO is a potent dopamine agonist drug of potential use in the treatment of Parkinson's disease.